Kiniksa Pharmaceuticals International (KNSA) Projected to Post Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.3722 per share and revenue of $260.21 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting analysts’ consensus estimates of $0.30. The firm had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, analysts expect Kiniksa Pharmaceuticals International to post $1.37 EPS for the current fiscal year and $2.07 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Trading Up 1.1%

Shares of NASDAQ:KNSA opened at $79.48 on Tuesday. The stock has a market capitalization of $6.20 billion, a P/E ratio of 81.94 and a beta of 0.04. Kiniksa Pharmaceuticals International has a 1-year low of $35.20 and a 1-year high of $82.98. The business has a 50-day moving average price of $77.93 and a two-hundred day moving average price of $64.29.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent research reports. The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Canaccord Genuity Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Wells Fargo & Company started coverage on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 price objective on the stock. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus price target of $93.14.

Insiders Place Their Bets

In related news, Director G. Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This represents a 13.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.